' We Need to Rethink Our Options': Lung Cancer Recurrence'We Need to Rethink Our Options': Lung Cancer Recurrence
Dr Mark Kris discusses the emerging issue of recurrence in the chest resulting from improved systemic therapies.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Neoadjuvant Bests Adjuvant Therapy in Lung Cancer Neoadjuvant Bests Adjuvant Therapy in Lung Cancer
Dr Mark Kris discusses neoadjuvant therapy for patients with lung cancer.Medscape Oncology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 24, 2024 Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Investor Update - April 24, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Media News - April 24, 2024 Category: Pharmaceuticals Source Type: news
Clinical practice LCS program finds more disease than NLST
Over a five-year period, a clinical practice lung cancer screening program at Duke University Medical Center in Durham, NC, found more disease than did the National Lung Screening Trial (NLST), researchers have reported.
The program showed a higher rate of lung cancer compared to the NLST’s, at 3.4% versus 2.4%. It also found more stage IV disease, wrote a team led by Kyle Lafata, PhD. The results were published April 23 in the Journal of the American College of Radiology.
“As LCS uptake increases, monitoring and tracking screening outcomes in clinical practice settings is key to high-quality screening and success,â€...
Source: AuntMinnie.com Headlines - April 24, 2024 Category: Radiology Authors: Kate Madden Yee Tags: CT Chest Radiology Source Type: news
Lung Cancer Cells Switch Oncogenic Drivers
Mouse models mimicking the transition from a common form of lung cancer to a more aggressive one may help scientists develop future strategies to prevent this transformation. (Source: The Scientist)
Source: The Scientist - April 23, 2024 Category: Science Tags: News News & Opinion Source Type: news
Novel risk prediction model improves LCS uptake
A novel risk prediction model used in the Ontario Lung Cancer Screening Pilot increased the uptake of lung cancer screening among eligible Canadians, researchers have found.
A team led by Martin C. Tammemägi, PhD, of Brock University in St. Catharines, Ontario, reported that use of the model translated to an adherence rate to annual recall and early surveillance scans and clinical investigations of more than 85%. The findings were published April 19 in Nature Medicine.
Lung cancer is the leading cause of cancer death around the world, and research has shown that low-dose CT (LDCT) lung cancer screening of high-risk indi...
Source: AuntMinnie.com Headlines - April 23, 2024 Category: Radiology Authors: Kate Madden Yee Tags: CT Chest Radiology Source Type: news
Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
MONDAY, April 22, 2024 -- The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 22, 2024 Category: Pharmaceuticals Source Type: news
Krystal Biotech moves to next step in clinical trial
Krystal Biotech has announced the first patient has joined a trial for its inhaled treatment for a solid lung cancer tumor. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 22, 2024 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news
Doctor's Quote "This Book Saved My Life" for a battle you cannot win alone
: "The Journey Through Cancer - A Postscript" provides the story and the process to confront a dreaded lung cancer diagnosis. LAYTONSVILLE, Md., April 20, 2024 /PRNewswire-PRWeb/ -- Press Release "Don't stop asking questions, and don't forget to pray for help and understanding in fighting... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 20, 2024 Category: Pharmaceuticals Source Type: news
BNSF Railway says it didn't know about asbestos that's killed hundreds in Montana town
BNSF Railway attorneys told a Montana jury Friday that the railroad should not be held liable for the lung cancer deaths of two former residents of an , one of the deadliest sites in the federal Superfund pollution program. Attorneys for the company say the corporate predecessors of the railroad,…#bnsfrailway #montana #superfund #warrenbuffett #bnsf #chadknight #libby #uscanada #maryland #brianmorris (Source: Reuters: Health)
Source: Reuters: Health - April 20, 2024 Category: Consumer Health News Source Type: news
Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC
(MedPage Today) -- The FDA extended indications for alectinib (Alecensa) to include adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first such approval for an ALK inhibitor.
The approval stipulates use of alectinib... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 19, 2024 Category: Hematology Source Type: news
Evergreen Theragnostics raises $26M
Evergreen Theragnostics has raised $26 million in capital through its existing shareholders and new backers Petrichor and LIFTT.
With the funding, the Springfield, NJ-based company plans to advance commercialization of its Ga-68 DOTATOC diagnostic kit, and further its theranostic pair, EVG-321, into clinical trials. Evergreen also intends to expand its capabilities as a contract development and manufacturing organization (CDMO).
Stefano Buono, chairman of LIFTT and founder and former CEO of Advanced Accelerator Applications, noted the funding is based on optimism around rapidly advancing radioligand therapies.
Evergreen...
Source: AuntMinnie.com Headlines - April 19, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Nuclear Radiology Radiation Oncology Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Investor Update - April 19, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Media News - April 19, 2024 Category: Pharmaceuticals Source Type: news
